経鼻ドラッグデリバリー技術の世界市場規模：製品タイプ別、容器別、用途別、エンドユーザー別、地域範囲別および予測

経鼻ドラッグデリバリー技術の市場規模と予測

経鼻ドラッグデリバリー技術の市場規模は2023年に769億2,000万米ドルと推計され、2031年には1,245億4,000万米ドルに達すると予測され、2024年から2031年までのCAGRは6.85%で成長します。経鼻ドラッグデリバリー技術は、鼻から薬剤を投与する技術であり、全身循環への直接アクセスを容易にします。この技術によってもたらされる利点には、患者のコンプライアンスが良好であること、嗅覚神経を介して脳に直接薬物を送達できる可能性があること、利便性が高いこと、血中の薬物濃度が治療レベルに迅速に到達することなどがあります。

経鼻ドラッグデリバリー市場は、自己投与の普及と慢性疾患の増加により、今後数年間で牽引されると予測されます。

同市場は、薬物投与の代替手段に対する嗜好の高まり、技術的進歩、新製品の革新、および予測期間中の市場成長を促進すると予測されるM&A活動から恩恵を受けると予測されます。

経鼻ドラッグデリバリー技術の世界市場力学

主な市場促進要因

慢性呼吸器疾患の有病率の上昇：

喘息、慢性閉塞性肺疾患（COPD）、アレルギー性鼻炎などの疾患の有病率が世界的に高まっており、呼吸器に直接薬剤を投与する非侵襲的で便利な方法に対する需要が急増しています。より迅速な吸収と患者のコンプライアンス向上のニーズが、経鼻ドラッグデリバリーソリューションの使用に拍車をかけています。

自己投与治療への需要の高まり：

利便性を高め、治療をコントロールするために、自己投与による投薬の選択肢を患者が求めるようになってきています。そのため、経鼻ドラッグデリバリーシステムはユーザーフレンドリーであることが多く、最小限のトレーニングしか必要としないため、自宅での自己投与に適しています。

ドラッグの製剤化とデリバリーにおける技術の進歩：

技術の進歩により、標的への送達、放出制御、およびバイオアベイラビリティ（血流に入る薬物の割合）の向上が改善された、新規の経鼻ドラッグデリバリーシステムの開発が容易になりつつあります。このような進歩は、より効果的で患者中心の治療選択肢の創出につながっています。

患者の利便性とコンプライアンスへの注目の高まり：

ヘルスケア業界では、患者の利便性を向上させ、治療レジメンを遵守させることが重視されるようになってきています。この点で、経鼻ドラッグデリバリーは、非侵襲性、使いやすさ、作用発現の速さなど、いくつかの利点があります。

主な課題

解剖学的・生理学的障壁の克服：

薬物の効率的な送達と分布は、狭い空間、粘液クリアランス機構、限られた吸収表面積など、鼻腔の複雑な構造に影響されます。

ドラッグデリバリーの安定性確保：

鼻腔内での薬物の分解は、酵素や粘液の存在によって促進されることが多いです。ドラッグデリバリーを鼻腔に投与するためには、これらの課題に対処するため、安定性と放出制御メカニズムについて慎重に検討する必要があります。

患者の受容性と使いやすさ：

点鼻薬やその他の送達デバイスの使いやすさは、特に小児や高齢の患者にとって極めて重要です。不快感、投与精度、鼻刺激などの潜在的な副作用などの問題に対処することは、患者に受け入れられるために不可欠です。

規制要件と厳しい試験：

経鼻ドラッグデリバリーシステムには、安全性、有効性、品質管理を含む厳しいガイドラインが規制機関によって課されています。コンプライアンスを遵守するためには、広範な前臨床試験と臨床試験が必要であり、これには時間とコストがかかります。

主要動向

非侵襲的で利便性の高いドラッグデリバリーに対する患者の嗜好の高まり：

非侵襲的で利便性の高いドラッグデリバリー法は、患者からますます求められています。経鼻ドラッグデリバリーには、経口薬や注射薬といった従来の方法に比べていくつかの利点があります。特に小児や高齢者にとっては、点鼻薬や点滴は錠剤や注射薬よりも一般的に使いやすいことが分かっています。また、経口薬と比較して、経鼻投与された薬物は血流に到達し、より迅速に効果を発揮することができます。

自己投与の普及：

薬の自己投与の動向は、ユーザーフレンドリーで便利な経鼻ドラッグデリバリーデバイスの需要を促進しています。この動向は、特にアレルギーや片頭痛などの慢性疾患で、患者が頻繁な薬剤投与を必要とする場合に関連します。遠隔医療や遠隔患者モニタリングの進歩により、接続型経鼻ドラッグデリバリーデバイスを使用する機会が生まれつつあります。これらのデバイスは薬の使用状況をモニターし、医療提供者にリアルタイムでデータを提供することができるため、患者のケア管理が強化されます。

在宅ヘルスケア機器の需要増加：

慢性疾患の有病率の上昇と在宅ヘルスケアへのシフトの高まりが、在宅ベースの経鼻ドラッグデリバリーデバイスの需要を促進しています。これらのデバイスにより、患者は自宅で治療を受けることができるため、生活の質が向上し、医療費が削減されます。

目次

第1章 世界の経鼻ドラッグデリバリー技術市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 経鼻ドラッグデリバリー技術の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析
• 規制の枠組み

第5章 経鼻ドラッグデリバリー技術の世界市場：容器別

• 概要
• 非加圧式
• 加圧式

第6章 経鼻ドラッグデリバリー技術の世界市場：製品タイプ別

• 概要
• スプレー
• 点滴
• ゲル
• 粉末
• 吸入剤

第7章 経鼻ドラッグデリバリー技術の世界市場：エンドユーザー別

• 概要
• 病院
• 診療所
• 外来手術センター
• 在宅医療
• その他

第8章 経鼻ドラッグデリバリー技術の世界市場：治療用途別

• 概要
• アレルギー性鼻炎
• 鼻づまり
• 感染症
• ワクチン接種
• オピオイド過剰摂取の回復
• その他

第9章 経鼻ドラッグデリバリー技術の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界の経鼻ドラッグデリバリー技術市場：競合情勢

• 概要
• 企業市場シェア
• ベンダー情勢
• 主な発展戦略

第11章 企業プロファイル

• Merck & Co., Inc.
• Novartis AG
• Glaxosmithkline PLC
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Astrazeneca PLC
• Aptargroup, Inc.
• Aegis Therapeutics LLC
• 3M
• Becton Dickinson and Company

第12章 主な発展

• 製品の上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第13章 付録

• 関連調査

Nasal Drug Delivery Technology Market Size And Forecast

Nasal Drug Delivery Technology Market size is estimated at USD 76.92 Billion in 2023 and is projected to reach USD 124.54 Billion by 2031 , growing at a CAGR of 6.85% from 2024 to 2031. Nasal drug delivery technology is a technique utilized for administering drugs through the nasal route, facilitating direct access to systemic circulation. Advantages offered by this technique include good patient compliance, the potential for direct drug delivery to the brain via the olfactory nerves, convenience, and rapid attainment of therapeutic drug levels in the blood.

The Nasal Drug Delivery Technology Market is expected to be driven by the growing adoption of self-administration and increasing incidences of chronic diseases over the predicted years.

The market is anticipated to benefit from the rising preference for an alternative mode of drug administration, technological advancements, new product innovations, and merger & acquisition activities, which are predicted to fuel market growth during the forecasted period.

Global Nasal Drug Delivery Technology Market Dynamics

The key market dynamics that are shaping the Nasal Drug Delivery Technology Market include:

Key Market Drivers

Rising Prevalence of Chronic Respiratory Diseases:

The growing prevalence of conditions like asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis worldwide is surging demand for a non-invasive and convenient way to administer medication directly to the respiratory tract. This need for faster absorption and improved patient compliance is spurring the use of nasal drug delivery solutions.

Growing Demand for Self-Administered Treatments:

Self-administered medication options are increasingly sought by patients for enhanced convenience and control over their treatment. Thus, nasal drug delivery systems are often user-friendly and require minimal training, making them suitable for self-administration at home.

Technological Advancements in Drug Formulation and Delivery:

Advancements in technology are facilitating the development of novel nasal drug delivery systems with improved targeted delivery, controlled release, and enhanced bioavailability (the proportion of a drug that enters the bloodstream). These advancements are leading to the creation of more effective and patient-centric treatment options.

Increasing Focus on Patient Convenience and Compliance:

The healthcare industry is witnessing a growing emphasis on improving patient convenience and compliance with treatment regimens. Nasal drug delivery offers several advantages in this regard, including its non-invasive nature, ease of use, and rapid onset of action.

Key Challenges

Overcoming Anatomical and Physiological Barriers:

The efficient delivery and distribution of drugs is affected by the complex structure of the nasal cavity, which includes narrow spaces, mucus clearance mechanisms, and limited absorption surface area.

Ensuring Drug Stability and Delivery:

Drug degradation in the nasal cavity is often facilitated by enzymes and the presence of mucus. Formulating drugs for nasal delivery requires careful consideration of stability and controlled release mechanisms to address these challenges.

Patient Acceptance and Usability:

User-friendliness of nasal sprays and other delivery devices is particularly crucial, especially for children or elderly patients. Addressing issues such as discomfort, dosing accuracy, and potential side effects like nasal irritation is essential for patient acceptance.

Regulatory Requirements and Stringent Testing:

Strict guidelines for nasal drug delivery systems, encompassing safety, efficacy, and quality control, are imposed by regulatory agencies. Compliance necessitates extensive preclinical and clinical testing, which can be both time-consuming and expensive.

Key Trends

Rising Patient Preference for Non-Invasive and Convenient Drug Delivery:

Non-invasive and convenient drug delivery methods are increasingly sought by patients. Several advantages are offered by nasal drug delivery over traditional methods such as oral or injectable medications. These advantages include: nasal sprays and drops are generally found to be easier to use than pills or injections, particularly for children or elderly patients, drugs administered nasally can reach the bloodstream and take effect more quickly compared to orally administered medications, and nasal delivery bypasses the digestive system, potentially minimizing side effects like nausea or stomach upset.

Growing Adoption of Self-Administration Practices:

The trend toward self-administration of medications is propelling the demand for user-friendly and convenient nasal drug delivery devices. This trend is particularly relevant for chronic conditions such as allergies or migraines, where patients may require frequent medication administration. Opportunities are emerging for the use of connected nasal drug delivery devices due to advancements in telemedicine and remote patient monitoring. These devices can monitor medication usage and furnish real-time data to healthcare providers, enhancing patient care management.

Increasing Demand for Home Healthcare Devices:

The rising prevalence of chronic diseases and the growing shift towards home healthcare are fueling the demand for home-based nasal drug delivery devices. These devices enable patients to receive treatment in their own homes, thereby enhancing their quality of life and reducing healthcare costs.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Nasal Drug Delivery Technology Market Regional Analysis

Here is a more detailed regional analysis of the Nasal Drug Delivery Technology Market:

North America

Novel nasal drug delivery technologies are heavily invested in by North American institutions, leading to market domination.

Approval of new technologies is expedited by favorable regulatory frameworks, such as the FDA's, solidifying North America's dominance.

Nasal drug delivery methods are widely accepted by the public, creating a strong North American market for new products.

Innovation and market growth in the nasal drug delivery sector are fueled by a thriving venture capital ecosystem, further strengthening North America's leading position.

Asia Pacific

Increasing investment in research and development by Asian Pacific institutions drives advancements in nasal drug delivery technology.

Regulatory reforms and streamlined approval processes in the region encourage the adoption of novel nasal drug delivery technologies.

Growing awareness and acceptance of nasal drug delivery methods among the population in the Asia Pacific contribute toward helping it grow at a rapid rate over the forecast period.

Global Nasal Drug Delivery Technology Market: Segmentation Analysis

The Global Nasal Drug Delivery Technology Market is Segmented on the basis of Product Type, Container, Application, End-Users, and Geography.

Nasal Drug Delivery Technology Market, By Product Type

• Sprays
• Drops
• Gels
• Powders
• Inhalers

Based on Product Type, the market is segmented into Sprays, Drops, Gels, Powders, and Inhalers. The highest market share in the Nasal Drug Delivery Technology Market is held by nasal sprays. Nasal sprays are favored due to their ease of administration, rapid onset of action, and suitability for delivering a wide range of medications, making them the preferred choice for both patients and healthcare providers. Their dominant position in the market is significantly contributed to by their versatility and effectiveness.

Nasal Drug Delivery Technology Market, By Application

• Allergic Rhinitis
• Congestion
• Infections
• Vaccination
• Opioid Overdose Reversal
• Others

Based on Application, the market is segmented into Allergic Rhinitis, Congestion, Infections, Vaccination, Opioid Overdose Reversal, and Others. The Nasal Drug Delivery Technology Market is dominated by Allergic Rhinitis. It is prevalent worldwide and drives the demand for nasal drug delivery systems due to the frequent need for medication administration. Nasal sprays are commonly utilized to alleviate allergic rhinitis symptoms because of their rapid onset of action and targeted delivery to the nasal mucosa.

Nasal Drug Delivery Technology Market, By End-Users

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Homecare Settings
• Others

Based on End-Users, the market is segmented into Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings, and Others. Homecare Settings dominate the Nasal Drug Delivery Technology Market. This dominance is attributed to the rising trend of self-administration and the convenience of using nasal drug delivery systems at home. Advancements in technology have enabled the development of user-friendly devices suitable for home use, further driving the demand in this segment.

Nasal Drug Delivery Technology Market, By Container

• Non-Pressurized
• Pressurized

Based on Container, the market is segmented into Non-Pressurized and Pressurized containers. Non-pressurized segment is anticipated to dominate the market over the forecast period. Growing concerns about environmental impact and potential health risks associated with propellants is surging demand for alternative delivery methods such as pumps or atomizer mechanisms.

Key Players

• The "Nasal Drug Delivery Technology Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
• Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Pfizer Inc., AstraZeneca PLC, AptarGroup Inc., Aegis Therapeutics LLC, 3M, Becton, Dickinson, and Company.

Our market analysis includes a section specifically devoted to such major players, where our analysts give an overview of each player's financial statements, along with product benchmarking and SWOT analysis. Key development strategies, market share analysis, and market positioning analysis of the aforementioned players globally are also included in the competitive landscape section.

• Nasal Drug Delivery Technology Market Recent Developments
• In October 2023, the launch of its Unidose+ nasal spray platform was announced by Aptar Pharma, a leading provider of drug delivery systems, specifically designed for high-viscosity and challenging-to-formulate drugs.
• In September 2023, a collaboration agreement was entered into by Vectura Group, a pharmaceutical company specializing in inhalation and nasal drug delivery, with ALX Oncology to develop and commercialize a novel nasal spray formulation of ALX148 for the treatment of head and neck cancers.
• In August 2023, the approval of AstraZeneca's RINVOQ nasal spray by the U.S. Food and Drug Administration (FDA) was announced, making it the first IL-12/23 inhibitor approved for the treatment of moderate-to-severe chronic rhinosinusitis with nasal polyps.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY CONTAINER

• 5.1 Overview
• 5.2 Non-Pressurized
• 5.3 Pressurized

6 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY PRODUCT TYPE

• 6.1 Overview
• 6.2 Sprays
• 6.3 Drops
• 6.4 Gels
• 6.5 Powders
• 6.6 Inhalers

7 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY END-USERS

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Ambulatory Surgical Centers
• 7.5 Homecare Settings
• 7.6 Others

8 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY THERAPEUTIC APPLICATION

• 8.1 Overview
• 8.2 Allergic Rhinitis
• 8.3 Congestion
• 8.4 Infections
• 8.5 Vaccination
• 8.6 Opioid Overdose Reversal
• 8.7 Others

9 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Share
• 10.3 Vendor Landscape
• 10.4 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Merck & Co., Inc.
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Novartis AG
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Glaxosmithkline PLC
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Johnson & Johnson Services, Inc.
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Pfizer Inc.
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Astrazeneca PLC
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Aptargroup, Inc.
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Aegis Therapeutics LLC
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 3M
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Becton Dickinson and Company
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 Appendix

• 13.1 Related Research